Merck And Eisai’s Keytruda/Lenvima/Welireg Trial In Kidney Cancer Fails

  
Merck and Eisai announced results from the LITESPARK-012 trial, saying that the trial did not meet either of its primary endpoints. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Trial Results

More from R&D